Troparil (beta-CPT / WIN 35065-2)
Troparil is a phenyltropane, a synthetic cocaine analogue developed as a research tool that acts as a potent, longer-lasting dopamine reuptake inhibitor. It has appeared on research-chemical markets as a cocaine-like stimulant, with extensive preclinical but essentially no human safety data.
01 Overview
Troparil (beta-CPT, WIN 35065-2) is one of the classic phenyltropanes synthesised to study the cocaine binding site at the dopamine transporter. Replacing cocaine's ester oxygen with a carbon makes it metabolically more stable and longer-acting.
There are no controlled human trials. Its pharmacology is well characterised in animals as a potent DAT inhibitor with cocaine-like reinforcing effects, predicting high abuse potential and cardiovascular risk in humans.
02 Mechanism
Potent dopamine (and norepinephrine) reuptake inhibitor; a phenyltropane cocaine analogue lacking the labile benzoyl ester.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common (approximate, anecdotal) | 5–20 mg | Oral | Potent; no validated human dosing. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Potent stimulationCocaine-like euphoria and energy, longer-lasting; documented in animals, reported anecdotally in humans. | Strong | Preclinical | |
| ReinforcementRobust self-administration in animal models predicts addictive potential. | Strong | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Cardiovascular toxicityTachycardia, hypertension and arrhythmia expected from potent stimulant action. | Severe | Unknown in humans | Unconfirmed | |
| Dependence and psychosis riskStrong reinforcement and dopaminergic drive risk dependence and paranoia. | Severe | Unknown | Unconfirmed |